A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT ID: NCT05748600
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
600 participants
INTERVENTIONAL
2023-01-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Phase III Long-Term Extension Study With Dexpramipexole
NCT06388889
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
NCT01000506
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
NCT03170271
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet
75 mg BID
Dexpramipexole 75 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet
Placebo
Placebo oral tablet taken twice a day
Placebo
administration of placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet
Placebo
administration of placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female ≥12 years of age at Screening Visit 1. Sites in Poland will only include participants aged ≥18 years.
Asthma-related criteria
3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
4. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Note: In Poland, this will instead include participants requiring a minimum daily medium dose ICS (≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021). Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1.
5. Pre-BD FEV1 ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2.
6. Bronchodilator reversibility, at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline.
7. ACQ-6 ≥1.5 at Screening Visit 2.
8. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2).
General medical history
9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits.
10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit:
1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive.
Or
2. Two protocol acceptable methods of contraception in tandem.
* Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply:
3. Women \<50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
4. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. least 7 days prior to baseline.
Exclusion Criteria
1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization prior to the Screening Visit 1 up to and including the Baseline Visit.
Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.
2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis).
3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1.
Prohibited medications/procedures
4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long acting anti-interleukin-5) in the past 12 months.
5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline.
7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1.
8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the study period.
General medical history
9. Weight \<40 kg at Screening Visit 2.
10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of \>10 packyears. Smoking includes tobacco, vaping, and/or marijuana use.
11. Known or suspected alcohol or drug abuse.
12. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to the Baseline Visit despite antihypertensive therapy.
13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit.
14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C.
15. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1, that has not been treated with or has failed to respond to standard of care therapy.
16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements.
17. Known or suspected noncompliance with medication.
18. Unwillingness or inability to follow the procedures outlined in the protocol.
Clinical safety labs
19. Absolute neutrophil count \<2.000x10⁹/L at Screening Visit 1 or Screening Visit 2..
20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[Levey et al, 2009\] for age ≥18 years at screening; using the Bedside Schwartz \[Schwartz and Work, 2009\] eGFR formula for age \<18).
21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
Cardiac safety
22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%.
23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit.
24. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation.
25. History of long QT syndrome.
26. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block.
27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including resting heart rate \<45 beats per minute (bpm) or \>100 bpm.
Pregnancy/Lactation
28. Pregnant women or women breastfeeding.
29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
For this study, rescreening may only be permitted under specific circumstances and only after contact with a Sponsor Clinical representative.
12 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Areteia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mona Bafadhel, MD
Role: PRINCIPAL_INVESTIGATOR
Guy's and St Thomas' NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site 40044-026
Rochdale, , United Kingdom
Research Site 40044-008
Salford, , United Kingdom
Research Site 40044-034
Stockport, , United Kingdom
Research Site 40044-078
Wythenshawe, , United Kingdom
Research Site 40380-016
Lutsk, , Ukraine
Research Site 40380-001
Ternopil, , Ukraine
Research Site 40380-003
Vinnytsia, , Ukraine
Research Site 40380-020
Vinnytsia, , Ukraine
Research Site 40380-008
Vinnytsia, , Ukraine
Research Site 40380-022
Vinnytsia, , Ukraine
Research Site 40380-005
Zhytomyr, , Ukraine
Research Site 40044-018
Bellshill, , United Kingdom
Research Site 40044-021
Birmingham, , United Kingdom
Research Site 40044-077
Bollington, , United Kingdom
Research Site 40044-017
Chorley, , United Kingdom
Research Site 40044-022
Enfield, , United Kingdom
Research Site 40044-019
Liverpool, , United Kingdom
Research Site 40044-084
London, , United Kingdom
Research Site 40044-001
Manchester, , United Kingdom
Research Site 40044-020
Manchester, , United Kingdom
Research Site 40044-013
Manchester, , United Kingdom
Research Site 40044-009
Manchester, , United Kingdom
Research Site 40044-036
Manchester, , United Kingdom
Research Site 40044-006
Manchester, , United Kingdom
Research Site 40044-024
Preston, , United Kingdom
Research Site 40001-487
Chandler, Arizona, United States
Research Site 40001-462
Peoria, Arizona, United States
Research Site 40001-322
Surprise, Arizona, United States
Research Site 40001-374
Bakersfield, California, United States
Research Site 40001-227
Encinitas, California, United States
Research Site 40001-349
Huntington Beach, California, United States
Research Site 40001-485
Inglewood, California, United States
Research Site 40001-440
La Palma, California, United States
Research Site 40001-357
Lancaster, California, United States
Research Site 40001-089
Los Angeles, California, United States
Research Site 40001-362
Mission Viejo, California, United States
Research Site 40001-449
Napa, California, United States
Research Site 40001-062
Newport Beach, California, United States
Research Site 40001-043
Newport Beach, California, United States
Research Site 40001-380
Redding, California, United States
Research Site 40001-434
San Diego, California, United States
Research Site 40001-088
San Jose, California, United States
Research Site 40001-359
Upland, California, United States
Research Site 40001-003
West Covina, California, United States
Research Site 40001-419
Westminster, California, United States
Research Site 40001-425
Aurora, Colorado, United States
Research Site 40001-353
Colorado Springs, Colorado, United States
Research Site 40001-385
Wheat Ridge, Colorado, United States
Research Site 40001-048
Aventura, Florida, United States
Research Site 40001-005
Brandon, Florida, United States
Research Site 40001-051
Brandon, Florida, United States
Research Site 40001-029
Coral Gables, Florida, United States
Research Site 40001-350
Gainesville, Florida, United States
Research Site 40001-014
Greenacres City, Florida, United States
Research Site 40001-054
Hialeah, Florida, United States
Research Site 40001-067
Hialeah, Florida, United States
Research Site 40001-020
Homestead, Florida, United States
Research Site 40001-015
Kissimmee, Florida, United States
Research Site 40001-002
Kissimmee, Florida, United States
Research Site 40001-086
Loxahatchee Groves, Florida, United States
Research Site 40001-318
Maitland, Florida, United States
Research Site 40001-066
Miami, Florida, United States
Research Site 40001-001
Miami, Florida, United States
Research Site 40001-059
Miami, Florida, United States
Research Site 40001-026
Miami, Florida, United States
Research Site 40001-288
Miami, Florida, United States
Research Site 40001-065
Miami, Florida, United States
Research Site 40001-024
Miami, Florida, United States
Research Site 40001-338
Miami Beach, Florida, United States
Research Site 40001-348
Ocala, Florida, United States
Research Site 40001-293
Orlando, Florida, United States
Research Site 40001-429
Plantation, Florida, United States
Research Site 40001-351
Sarasota, Florida, United States
Research Site 40001-069
St. Petersburg, Florida, United States
Research Site 40001-370
Tallahassee, Florida, United States
Research Site 40001-004
Tampa, Florida, United States
Research Site 40001-319
Viera, Florida, United States
Research Site 40001-142
Adairsville, Georgia, United States
Research Site 40001-075
Augusta, Georgia, United States
Research Site 40001-018
Columbus, Georgia, United States
Research Site 40001-452
Dunwoody, Georgia, United States
Research Site 40001-483
East Point, Georgia, United States
Research Site 40001-366
Lilburn, Georgia, United States
Research Site 40001-423
Savannah, Georgia, United States
Research Site 40001-090
Berwyn, Illinois, United States
Research Site 40001-343
Chicago, Illinois, United States
Research Site 40001-358
Normal, Illinois, United States
Research Site 40001-135
River Forest, Illinois, United States
Research Site 40001-403
Skokie, Illinois, United States
Research Site 40001-036
Elwood, Indiana, United States
Research Site 40001-347
Louisville, Kentucky, United States
Research Site 40001-019
Owensboro, Kentucky, United States
Research Site 40001-437
Alexandria, Louisiana, United States
Research Site 40001-313
Marrero, Louisiana, United States
Research Site 40001-352
Zachary, Louisiana, United States
Research Site 40001-417
Annapolis, Maryland, United States
Research Site 40001-466
Baltimore, Maryland, United States
Research Site 40001-456
Takoma Park, Maryland, United States
Research Site 40001-055
White Marsh, Maryland, United States
Research Site 40001-468
Fall River, Massachusetts, United States
Research Site 40001-427
Dearborn, Michigan, United States
Research Site 40001-006
Flint, Michigan, United States
Research Site 40001-148
Flint, Michigan, United States
Research Site 40001-463
Rochester Hills, Michigan, United States
Research Site 40001-442
Southfield, Michigan, United States
Research Site 40001-372
Warren, Michigan, United States
Research Site 40001-421
Mankato, Minnesota, United States
Research Site 40001-083
Columbia, Missouri, United States
Research Site 40001-074
Saint Charles, Missouri, United States
Research Site 40001-046
St Louis, Missouri, United States
Research Site 40001-409
Missoula, Montana, United States
Research Site 40001-448
Lincoln, Nebraska, United States
Research Site 40001-404
Omaha, Nebraska, United States
Research Site 40001-473
Las Vegas, Nevada, United States
Research Site 40001-387
Brick, New Jersey, United States
Research Site 40001-363
Edison, New Jersey, United States
Research Site 40001-457
Jersey City, New Jersey, United States
Research Site 40001-355
Toms River, New Jersey, United States
Research Site 40001-050
East Amherst, New York, United States
Research Site 40001-412
Great Neck, New York, United States
Research Site 40001-047
Hawthorne, New York, United States
Research Site 40001-455
New York, New York, United States
Research Site 40001-369
New York, New York, United States
Research Site 40001-408
Charlotte, North Carolina, United States
Research Site 40001-398
Charlotte, North Carolina, United States
Research Site 40001-039
Gastonia, North Carolina, United States
Research Site 40001-435
Greenville, North Carolina, United States
Research Site 40001-111
Huntersville, North Carolina, United States
Research Site 40001-382
Raleigh, North Carolina, United States
Research Site 40001-439
Rocky Mount, North Carolina, United States
Research Site 40001-283
Winston-Salem, North Carolina, United States
Research Site 40001-034
Cincinnati, Ohio, United States
Research Site 40001-013
Cincinnati, Ohio, United States
Research Site 40001-010
Cincinnati, Ohio, United States
Research Site 40001-413
Cleveland, Ohio, United States
Research Site 40001-017
Dayton, Ohio, United States
Research Site 40001-063
Toledo, Ohio, United States
Research Site US-40001-038
Edmond, Oklahoma, United States
Research Site 40001-386
Oklahoma City, Oklahoma, United States
Research Site 40001-079
Oklahoma City, Oklahoma, United States
Research Site 40001-027
Grants Pass, Oregon, United States
Research Site 40001-337
Portland, Oregon, United States
Research Site 40001-395
Hershey, Pennsylvania, United States
Research Site 40001-327
Philadelphia, Pennsylvania, United States
Research Site 40001-032
Columbia, South Carolina, United States
Research Site 40001-025
Greenville, South Carolina, United States
Research Site 40001-430
Rock Hill, South Carolina, United States
Research Site 40001-073
Spartanburg, South Carolina, United States
Research Site 40001-438
Dickson, Tennessee, United States
Research Site 40001-414
Franklin, Tennessee, United States
Research Site 40001-334
Allen, Texas, United States
Research Site 40001-068
Amarillo, Texas, United States
Research Site 40001-023
Dallas, Texas, United States
Research Site 40001-028
Dallas, Texas, United States
Research Site 40001-415
Dallas, Texas, United States
Research Site 40001-304
DeSoto, Texas, United States
Research Site 40001-418
Frisco, Texas, United States
Research Site 40001-064
Houston, Texas, United States
Research Site 40001-085
Houston, Texas, United States
Research Site 40001-424
Kerrville, Texas, United States
Research Site 40001-295
McKinney, Texas, United States
Research Site 40001-304
Red Oak, Texas, United States
Research Site 40001-377
San Antonio, Texas, United States
Research Site 40001-335
Sugar Land, Texas, United States
Research Site 40001-258
Murray, Utah, United States
Research Site 40001-333
Pleasant View, Utah, United States
Research Site 40001-340
Burke, Virginia, United States
Research Site 40001-394
Williamsburg, Virginia, United States
Research Site 40001-339
Greenfield, Wisconsin, United States
Research Site 40001-433
La Crosse, Wisconsin, United States
Research Site 40001-443
La Crosse, Wisconsin, United States
Research Site 40054-035
Buenos Aires, , Argentina
Research Site 40054-044
Buenos Aires, , Argentina
Research Site 40054-034
Buenos Aires, , Argentina
Research Site 40054-017
Buenos Aires, , Argentina
Research Site 40054-008
Buenos Aires, , Argentina
Research Site 40054-043
Buenos Aires, , Argentina
Research Site 40054-015
Caba, , Argentina
Research Site 40054-019
Mendoza, , Argentina
Research Site 40054-016
Mendoza, , Argentina
Research Site 40054-010
Mendoza, , Argentina
Research Site 40054-028
Mendoza, , Argentina
Research Site 40054-032
Mendoza, , Argentina
Research Site 40054-057
Mendoza, , Argentina
Research Site 40054-024
San Miguel de Tucumán, , Argentina
Research Site 40054-002
San Miguel de Tucumán, , Argentina
Research Site 40054-020
San Miguel de Tucumán, , Argentina
Research Site 30043-013
Salzburg, , Austria
Research Site 40055-015
Belo Horizonte, , Brazil
Research Site 40055-007
Blumenau, , Brazil
Research Site 40055-011
Campo Largo, , Brazil
Research Site 40055-043
Curitiba, , Brazil
Research Site 40055-036
Curitiba, , Brazil
Research Site 40055-012
Porto Alegre, , Brazil
Research Site 40055-004
Porto Alegre, , Brazil
Research Site 40055-010
Porto Alegre, , Brazil
Research Site 40055-035
Rio de Janeiro, , Brazil
Research Site 40055-025
Salvador, , Brazil
Research Site 40055-005
Santo André, , Brazil
Research Site 40055-009
Santos, , Brazil
Research Site 40055-001
São Bernardo do Campo, , Brazil
Research Site 40011-004
Ajax, Ontario, Canada
Research Site 40011-016
Ajax, Ontario, Canada
Research Site 40011-010
Burlington, Ontario, Canada
Research Site 40011-014
Ottawa, Ontario, Canada
Research Site 40011-005
Windsor, Ontario, Canada
Research Site 40011-001
Windsor, Ontario, Canada
Research Site 40011-018
Montreal, Quebec, Canada
Research Site 40011-022
Québec, Quebec, Canada
Research Site 40011-020
Trois-Rivières, Quebec, Canada
Research Site 40011-011
Vancouver, , Canada
Research Site 40972-010
Ashkelon, , Israel
Research Site 40972-008
Beersheba, , Israel
Research Site 40972-005
Haifa, , Israel
Research Site 40972-004
Haifa, , Israel
Research Site 40972-001
Jerusalem, , Israel
Research Site 40972-009
Kfar Saba, , Israel
Research Site 40972-002
Petah Tikva, , Israel
Research Site 40972-011
Ramat Gan, , Israel
Research Site 30060-006
Kampung Kelantan, , Malaysia
Research Site 40052-026
Chihuahua City, , Mexico
Research Site 40052-007
Guadalajara, , Mexico
Research Site 40052-028
Mexico City, , Mexico
Research Site 40052-012
San Juan del Río, , Mexico
Research Site 40048-001
Będzin, , Poland
Research Site 40048-018
Bialystok, , Poland
Research Site 40048-032
Bialystok, , Poland
Research Site 40048-023
Gdansk, , Poland
Research Site 40048-006
Giżycko, , Poland
Research Site 40048-021
Katowice, , Poland
Research Site 40048-002
Katowice, , Poland
Research Site 40048-027
Krakow, , Poland
Research Site 40048-033
Krakow, , Poland
Research Site 40048-008
Krakow, , Poland
Research Site 40048-040
Krakow, , Poland
Research Site 40048-015
Lodz, , Poland
Research Site 40048-009
Lodz, , Poland
Research Site 40048-005
Lodz, , Poland
Research Site 40048-022
Lublin, , Poland
Research Site 40048-024
Maków Podhalański, , Poland
Research Site 40048-031
Ostrowiec Świętokrzyski, , Poland
Research Site 40048-010
Piaseczno, , Poland
Research Site 40048-016
Poznan, , Poland
Research Site 40048-039
Rzeszów, , Poland
Research Site 40048-014
Skierniewice, , Poland
Research Site 40048-012
Trzebnica, , Poland
Research Site 40048-019
Wroclaw, , Poland
Research Site 40787-365
Guaynabo, , Puerto Rico
Research Site 40787-390
Ponce, , Puerto Rico
Research Site 40787-388
San Juan, , Puerto Rico
Research Site 40787-383
San Juan, , Puerto Rico
Research Site 40787-405
San Juan, , Puerto Rico
Research Site 40787-360
San Juan, , Puerto Rico
Research Site 40787-345
Vega Baja, , Puerto Rico
Research Site 40040-004
Brasov, Brașov County, Romania
Research Site 40040-006
Cluj-Napoca, Cluj, Romania
Research Site 40040-002
Brasov, , Romania
Research Site 40040-009
Cluj-Napoca, , Romania
Research Site 40040-007
Cluj-Napoca, , Romania
Research Site 40040-001
Constanța, , Romania
Research Site 40040-010
Sângeorgiu de Mureş, , Romania
Research Site 40040-003
Timișoara, , Romania
Research Site 40027-013
Benoni, , South Africa
Research Site 40027-025
Cape Town, , South Africa
Research Site 40027-009
Cape Town, , South Africa
Research Site 40027-011
Cape Town, , South Africa
Research Site 40027-021
Cape Town, , South Africa
Research Site 30090-020
Durban, , South Africa
Research Site 40027-007
Durban, , South Africa
Research Site 40027-026
Johannesburg, , South Africa
Research Site 40027-005
KwaZulu, , South Africa
Research Site 40027-008
KwaZulu, , South Africa
Research Site 40027-020
KwaZulu, , South Africa
Research Site 40027-023
KwaZulu, , South Africa
Research Site 40027-027
KwaZulu, , South Africa
Research Site 40027-010
KwaZulu, , South Africa
Research Site 40027-006
Mpumalanga, , South Africa
Research Site 40027-004
Pretoria, , South Africa
Research Site 40027-019
Pretoria, , South Africa
Research Site 40027-018
Vereeniging, , South Africa
Research Site 40027-017
Welkom, , South Africa
Research Site 40082-003
Anyang-si, , South Korea
Research Site 30082-024
Bucheon-si, , South Korea
Research Site 40082-007
Busan, , South Korea
Research Site 40082-021
Gwangju, , South Korea
Research Site 40082-020
Incheon, , South Korea
Research Site 40082-006
Jeonju, , South Korea
Research Site 40082-019
Seoul, , South Korea
Research Site 40082-012
Seoul, , South Korea
Research Site 40082-008
Seoul, , South Korea
Research Site 40082-004
Seoul, , South Korea
Research Site 40082-011
Seoul, , South Korea
Research Site 40082-010
Suwon, , South Korea
Research Site 40886-001
Kaohsiung City, , Taiwan
Research Site 40886-004
New Taipei City, , Taiwan
Research Site 40886-006
New Taipei City, , Taiwan
Research Site 40886-005
Taichung, , Taiwan
Research Site 40886-007
Taichung, , Taiwan
Research Site 40886-010
Taipei, , Taiwan
Research Site 40886-008
Taipei, , Taiwan
Research Site 40866-003
Taipei, , Taiwan
Research Site 40886-009
Taipei, , Taiwan
Research Site 30066-004
Pathum Thani, , Thailand
Research Site 40090-002
Adana, , Turkey (Türkiye)
Research Site 40090-018
Ankara, , Turkey (Türkiye)
Research Site 40090-021
Ankara, , Turkey (Türkiye)
Research Site 40090-024
Ankara, , Turkey (Türkiye)
Research Site 40090-003
Ankara, , Turkey (Türkiye)
Research Site 40090-025
Ankara, , Turkey (Türkiye)
Research Site 40090-008
Ankara, , Turkey (Türkiye)
Research Site 40090-009
Ankara, , Turkey (Türkiye)
Research Site 40090-017
Antalya, , Turkey (Türkiye)
Research Site 40090-019
Bornova, , Turkey (Türkiye)
Research Site 40090-020
Istanbul, , Turkey (Türkiye)
Research Site 40090-026
Istanbul, , Turkey (Türkiye)
Research Site 40090-011
Istanbul, , Turkey (Türkiye)
Research Site 40090-012
Konak, , Turkey (Türkiye)
Research Site 40090-016
Merkez, , Turkey (Türkiye)
Research Site 40090-013
Mersin, , Turkey (Türkiye)
Research Site 40090-024
Pendik, , Turkey (Türkiye)
Research Site 40090-022
Tekirdağ, , Turkey (Türkiye)
Research Site 40380-002
Chernivtsi, , Ukraine
Research Site 40380-021
Chernivtsi, , Ukraine
Research Site 40380-009
Ivano-Frankivsk, , Ukraine
Research Site 40380-004
Ivano-Frankivsk, , Ukraine
Research Site 40380-017
Ivano-Frankivsk, , Ukraine
Research Site 40380-014
Ivano-Frankivsk, , Ukraine
Research Site 40380-019
Kyiv, , Ukraine
Research Site 40380-018
Kyiv, , Ukraine
Research Site 40380-007
Kyiv, , Ukraine
Research Site 40380-010
Kyiv, , Ukraine
Research Site 40380-012
Kyiv, , Ukraine
Research Site 40380-015
Kyiv, , Ukraine
Research Site 40380-011
Kyiv, , Ukraine
Research Site 40380-013
Kyiv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003005-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AR-DEX-22-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.